SCHEMBL971316

SCHEMBL971316

NCCc1occ2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.37
TAAR1 Q96RJ0 9/20 0.37
LOXL2 Q9Y4K0 3/20 0.37
CYP2A6 P11509 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HTR1B P28222 3/20 0.35
MPO P05164 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
NFKB1 P19838 1/20 0.35
HTR1D P28221 1/20 0.35
HTR2C P28335 1/20 0.35
HTR7 P34969 1/20 0.35
CTSK P43235 1/20 0.35
HTR6 P50406 1/20 0.35
CYP2A13 Q16696 1/20 0.35
CA12 O43570 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3983271 0.89 HTR1B (0.40) HTR2ALOXL2SMN1; SMN2HTR1BMPO
SCHEMBL9739681 0.83 HTR2A (0.43) HTR2ATAAR1LOXL2CYP2A6HTR1B
SCHEMBL6591672 0.80 ALDH1A1 (0.32) CYP2A6ALDH1A1TSHRHSD17B10
SCHEMBL2961433 0.80 TDP1 (0.37) CYP2A6HTR1BCYP1A2HTR1DALDH1A1
SCHEMBL13183865 0.80 KDM4E (0.41) CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10
SCHEMBL6002752 0.77 MAPT (0.30) CYP2A6ALDH1A1TSHRHSD17B10MAPT
SCHEMBL16684493 0.77 MAPT (0.43) GAAMAPT
SCHEMBL28869124 0.77 KDM4E (0.38) ALDH1A1TSHRHSD17B10KDM4EGAA
SCHEMBL7140950 0.77 EGFR (0.41) MPOCYP1A2CYP3A4CYP2D6KDM4E
SCHEMBL10596740 0.76 KDM4E (0.40) ALDH1A1TSHRHSD17B10KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7632861-B2 1-Isobenzofuranethanamine, 1-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]methyl]-1,3-dihydro-N,N-dimethyl-; use in treating a disorder associated with aberrant levels of tachykinins or serotonin; nerve system disorders BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-15 US claimed
WO-2009064684-A1 SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-05-22 WO claimed
US-20090124613-A1 Substituted Heterocyclic Ethers and Their Use in CNS Disorders BRISTOL-MYERS SQUIBB COMPANY 2009-05-14 US claimed
US-8304543-B2 Blocking agents for organoborane compounds DOW GLOBAL TECHNOLOGIES LLC (US) 2012-11-06 US disclosed
US-8304543-B2 Blocking agents for organoborane compounds DOW GLOBAL TECHNOLOGIES LLC (US) 2012-11-06 US disclosed
EP-2350099-A1 BLOCKING AGENTS FOR ORGANOBORANE COMPOUND Dow Global Technologies LLC (US) 2011-08-03 EP disclosed
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2011-01-06 US disclosed
US-20100105910-A1 BLOCKING AGENTS FOR ORGANOBORANE COMPOUNDS DOW GLOBAL TECHNOLOGIES INC. (US) 2010-04-29 US disclosed
US-20100105910-A1 BLOCKING AGENTS FOR ORGANOBORANE COMPOUNDS DOW GLOBAL TECHNOLOGIES INC. (US) 2010-04-29 US disclosed
WO-2010048323-A1 BLOCKING AGENTS FOR ORGANOBORANE COMPOUND DOW GLOBAL TECHNOLOGIES INC. (US) 2010-04-29 WO disclosed
WO-2010048323-A1 BLOCKING AGENTS FOR ORGANOBORANE COMPOUND DOW GLOBAL TECHNOLOGIES INC. (US) 2010-04-29 WO disclosed
EP-2162451-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES Neurogen Corporation (US) 2010-03-17 EP disclosed
WO-2009003003-A2 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-12-31 WO disclosed
EP-1537122-B9 ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES WYETH CORP (US) 2007-10-31 EP disclosed
EP-1537122-B1 ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES WYETH CORP (US) 2007-08-22 EP disclosed
EP-1537122-A1 ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES Wyeth (US) 2005-06-08 EP disclosed
US-6800637-B2 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines WYETH 2004-10-05 US disclosed
US-20040138222-A1 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines WYETH 2004-07-15 US disclosed
WO-2004024734-A1 ANTIDEPRESSANT INDOLEALKYL DERIVATIVES OF HETEROCYCLE-FUSED BENZODIOXAN METHYLAMINES WYETH (US) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002855-A1 PIPERAZINYL OXOALKYL TETRAHYDRO-BETA-CARBOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 HTR2A 108/4885TAAR1 116/4885LOXL2 1392/4885
US-20100105910-A1 BLOCKING AGENTS FOR ORGANOBORANE COMPOUNDS NMBR, TBCB, GABBR1 HTR2A 2875/4885TAAR1 276/4885LOXL2 1662/4885
US-20040138222-A1 Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines HTR5A, TPH1, DBH HTR2A 23/4885TAAR1 50/4885LOXL2 4115/4885
US-20090124613-A1 Substituted Heterocyclic Ethers and Their Use in CNS Disorders CNR1, CNR2, PMP22 HTR2A 226/4885TAAR1 205/4885LOXL2 2893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.